Testicular germ cell tumors

Journal of B.U.ON.

Volumn 15, Issue 3, 2010, Pages 421-434

  Diamantopoulos, Nikolaos ^a   Kortsaris, A ^b  

^a PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Diagnosis; Germ cell tumors; Pathogenesis; Risk factors; Testicular cancer; Treatment

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CARBOPLATIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; LACTATE DEHYDROGENASE; OXALIPLATIN; PACLITAXEL; TUMOR MARKER; VINBLASTINE;

ADULT; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AZOOSPERMIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CRYPTORCHISM; DIAGNOSTIC IMAGING; DIETARY INTAKE; DRUG MEGADOSE; ENVIRONMENTAL FACTOR; ETHNIC DIFFERENCE; FAMILY HISTORY; FOLLOW UP; GERM CELL TUMOR; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOHISTOCHEMISTRY; INCIDENCE; LEUKEMIA; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MALE INFERTILITY; METASTASIS; MORTALITY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OTOTOXICITY; PATHOGENESIS; PATIENT MONITORING; PERIODIC MEDICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PROGNOSIS; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SECOND CANCER; SEMINOMA; SERUM; SOLID TUMOR; TESTIS ATROPHY; TESTIS CANCER; TESTIS TUMOR; TUMOR CLASSIFICATION; TUMOR VOLUME; ULTRASOUND;

FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; RISK FACTORS; TESTICULAR NEOPLASMS;

EID: 77957745930     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (137)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J Urol 2003; 170: 5-11. (Pubitemid 36734401)
3. Dearnaley DP, Huddart RA, Horwich A. Clinical Review: Managing Testicular Cancer. BMJ 2001; 322: 1583-1588.
4. Ries, LA, Eisner, MP, Kosary, CL et al. SEER Cancer Statistics Review, 1975-2001. National Cancer Institute, Bethesda, MD, 2004.
5. Parkin DM, Whelan SL, Ferlay J et al. Cancer incidence in five continents. Lyon: IARC Scientific Publications, 1997, vol VII.
6. Garner M, Turner M, Ghadirian P et al. Epidemiology of testicular cancer: an overview. Int J Cancer 2005: 116: 331-339.
7. Bray F, Richiardi L, Ekbom A, Pukkala E, Cuninkova M, Møller H. Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. Int J Cancer 2006; 118: 3099-3111.
8. Nichols CR, Fox EP. Extragonadal and pediatric germ cell tumors. Hematol Oncol Clin North Am 1991; 5: 1189-1209.
9. Carriere P, Baade P, Fritschi L. Population based incidence and age distribution of spermatocytic seminoma. J Urol 2007; 178: 125-128.
10. Vural F, Cagirgan S, Saydam A et al. Primary testicular lymphoma. J Natl Med Assoc 2007; 99: 1277-1282.
11. Liu S, Semenciw R, Waters C. Clues to the etiological heterogeneity of testicular seminomas and non-seminomas: time trends and age-period cohort effects. Int J Epidemiol 2000; 29: 826-831.
12. Hoei-Hansen CE, Rajpert-De Meyts E, Daugaard G, Skakkebaek NE. Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. Ann Oncol 2005; 16: 863.
13. Dieckmann KP, Classen J, Souchon R, Loy V. Management of testicular intraepithelial neoplasia (TIN) -a review based on the principles of evidence-based medicine. Wien Klin Wochenschr 2001; 113: 7-14.
14. Swerdlow AJ, Higgins CD, Pike MC. Risk of testicular cancer in cohort of boys with cryptorchidism. Br Med J 1997; 314: 1507.
15. Moller H, Prener A, Skakkebaek NE. Testicular cancer, cryptorchidism, inguinal hernia, testicular atrophy, and genital malformations: case-control studies in Denmark. Cancer Causes Control 1996; 7: 264-274.
16. Fossa SD, Chen J, Schonfeld SJ et al. Risk of contralateral testicular cancer a population-based study of 29,515 US men. J Natl Cancer Inst 2005; 97: 1056-1066. (Pubitemid 41417922)
17. Hartmann JT, Fossa SD, Nichols CR, Droz JP. Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors. J Natl Cancer Inst 2001; 93: 1733-1738. (Pubitemid 33130262)
18. Lutke Holzik MF, Rapley EA, Hoekstra HJ et al. Genetic pre-disposition to testicular germ-cell tumors. Lancet Oncol 2004; 5: 363-371 (Review).
19. Rapley EA, Crockford GP, Easton DF et al. Localization to Xq27 of a susceptibility gene for testicular germ cell tumors. Nat Genet 2000; 24: 197-200.
20. Gourlay WA, Johnson HW, Pantzar JT et al. Gonadal tumors in disorders of sexual differentiation. Urology 1994; 43: 537-540.
21. Powles T, Bower M, Daugaard G et al. Multicenter study of human immunodeficiency virus-related germ cell tumors. J Clin Oncol 2003; 21: 1922-1927.
22. Jacobsen R, Bostofte E, Engholm G et al. Risk of testicular cancer in men with abnormal semen characteristics. Br Med J 2000; 321: 789-792.
23. Sigg C, Pelloni F. Dysplastic nevi and germ cell tumors of the testis - a possible further tumor in the spectrum of associated malignancies in dysplastic nevus syndrome. Dermatologica 1988; 176: 109-110.
24. Ehrengut W, Schwartau M. Mumps orchitis and testicular tumours. Br Med J 1977; 2: 191.
25. Dieckmann KP, Rube C, Henke RP. Association of Down's syndrome and testicular cancer. J Urol 1997; 157: 1701-1704.
26. Hasle H, Mellemgaard A, Nielsen J, Hansen J. Cancer incidence in men with Klinefelter syndrome. Br J Cancer 1995; 71: 416-420.
27. Wilson DM, Pitts WC, Hintz RL, Rosenfeld RG. Testicular tumors with Peutz-Jeghers syndrome. Cancer 1986; 57: 2238-2240. (Pubitemid 16121764)
28. Carney JA. Carney complex: The complex of myxomas, spotty pigmentation, endocrine overactivity and schwannomas. Semin Dermatol 1995; 14: 90-98.
29. Garner MJ, Birkett NJ, Johnson KC et al. Dietary risk factors for testicular carcinoma. Int J Cancer 2003; 106: 934-941.
30. Akre O, Ekbom A, Hsieh CC et al. Testicular nonseminoma and seminoma in relation to perinatal characteristics. J Natl Cancer Inst 1996; 88: 883-889. (Pubitemid 26230639)
31. Herbst H, Sauter M, Kühler-Obbarius C et al. Human endogenous retrovirus (HERV)-K transcripts in germ cell and trophoblastic tumours. APMIS 1998; 106: 216-220. (Pubitemid 28123358)
32. Moller H, Knudsen LB, Lynge E. Risk of testicular cancer after vasectomy: cohort study of over 73,000 men. Br Med J 1994; 309: 2959.
33. Skakkebaek NE, Berethelsen JG, Giwercman A, Muller J. Carcinoma in situ: possible origin from gonocytes and precursor of all types of germ cell tumours except spermatocytoma. Int J Androl 1987; 10: 19-28.
34. Houldsworth J, Korkola JE, Bosl GJ et al. Biology and genetics of adult male germ cell tumors. J Clin Oncol 2006; 24: 5512-5528. (Pubitemid 46631331)
35. van Gurp RJ, Oosterhuis JW, Kalscheuer V et al. Biallelic expression of the H19 and IGF2 genes in human testicular germ cell tumors. J Natl Cancer Inst 1994; 86: 1070-1075. (Pubitemid 24228474)
36. Henegariu O, Heerema NA, Thurston V et al. Characterization of gains, losses and regional amplification in testicular germ cell tumor cell lines by comparative genomic hybridization. Cancer Genet Cytogenet 2004; 148: 14-20.
37. Atkin NB, Baker MC. i(12p): specific chromosomal marker in seminoma and malignant teratoma of the testis?. Cancer Genet Cytogenet 1983; 10: 199-204.
38. Sakuma Y, Matsukuma S, Yoshihara M et al. Mutations of c-kit gene in bilateral testicular germ cell tumours in Japan. Cancer Lett 2008; 259: 119-126.
39. Mostert MC, Verkerk AJ, van der Pol M et al. Identification of the critical region of 12p over-representation in testicular germ cell tumors of adolescents and adults. Oncogene 1998; 16: 2617-2627.
40. Weinstein M. Molecular genetics of testicular germ cell tumors. Retrieved Nov 15 2009 from UpToDate edition 17.3 online textbook: http://www.uptodate.com
41. Albanell J, Bosl GJ, Reuter VE et al. Telomerase activity in germ cell cancers and mature teratomas. J Natl Cancer Inst 1999; 91: 1321-1326. (Pubitemid 29387575)
42. Houldsworth J, Xiao H, Murty VV et al. Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene 1998; 16: 2345-2349.
43. Rosenberg C, Mostert MC, Schut TB et al. Chromosomal constitution of human spermatocytic seminomas: comparative genomic hybridization supported by conventional and interphase cytogenetics. Genes Chromosomes Cancer 1998; 23: 286-291. (Pubitemid 28507367)
44. Henderson BE, Ross RK, Pike MC et al. Epidemiology of testis cancer. In: Skinner DG (Ed): Urological Cancer. New York: Grune and Stratton; 1983, pp 237-250.
45. Rajpert-De Meyts E, Skakkebaek NE. The possible role of sex hormones in the development of testicular cancer. Eur Urol 1993; 23: 54-59; discussion 60-61.
46. Raghavan D, Neville M. Biology of Germ Cell Tumors. In: American Cancer Society Atlas of Clinical Oncology: Germ Cell Tumors, BC Decker Inc 2003, pp 1-15.
47. Marth D, Scheidegger J, Studer UE. Ultrasonography of testicular tumors. Urol Int 1990; 45: 237-240.
48. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997; 337: 242-53. Review. Erratum in: N Engl J Med 1997; 337: 1403.
49. Donohue JP, Zachary JM, Maynard BR. Distribution of nodal metastases in nonseminomatous testis cancer. J Urol 1982; 128: 315-320.
50. Weinstein MH. Lymphatic Drainage of the Testes. In: Rowland RG (Ed): Atlas of the Urologic Clinics of North America. Testis Cancer. WB Saunders Co, Philadelphia 1999.
51. Huddart R, Kataja V. ESMO Guidelines Working Group. Testicular seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19 (Suppl 2): ii49-51.
52. Huddart R, Kataja V. ESMO Guidelines Working Group. Mixed or non-seminomatous germ-cell tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19 (Suppl 2): ii52-54.
53. Ulbright TM, Amin MB, Young RH. Tumors of the Testis, Adnexa, Spermatic Cord, and Scrotum. In: Rosai J, Sobin LH (Eds): Atlas of Tumor Pathology (3rd Edn). Armed Forces Institute of Pathology, Washington, DC, 1999.
54. Ulbright TM. The most common, clinically significant misdiagnoses in testicular tumor pathology, and how to avoid them. Adv Anat Pathol 2008; 15: 18-27.
55. Ulbright TM. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod Pathol 2005; 18 (Suppl 2): S61-79 (Review).
56. Bower M, Rustin GJ. Serum tumor markers and their role in monitoring germ cell cancers of the testis. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (Eds): Comprehensive Textbook of Genitourinary Oncology (2nd Edn). Lippincott, Williams and Wilkins, Philadelphia, 2000, p 931.
57. Toner GC. Early identification of therapeutic failure in non-seminomatous germ cell tumors by assessing serum tumor marker decline during chemotherapy: still not ready for routine clinical use. J Clin Oncol 2004; 22: 3868-3876.
58. AJCC (American Joint Committee on Cancer) Cancer Staging Manual (6th Edn). Greene FL, Page DL, Fleming ID et al (Eds). Springer-Verlag, New York, 2002.
59. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15: 594-603.
60. Petersen PM, Skakkebaek NE, Rorth M, Giwercman A. Semen quality and reproductive hormones before and after orchiectomy in men with testicular cancer. J Urol 1999; 161: 822-826. (Pubitemid 29422375)
61. Warde P, Specht L, Horwich A et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002; 20: 4448-4452. (Pubitemid 35334756)
62. Choo R, Thomas G, Woo T et al. Long-term outcome of postorchiectomy surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys 2005; 61: 736-740. (Pubitemid 40247967)
63. Jones WG, Fossa SD, Mead GM et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 2005; 23: 1200-1208.
64. Oliver RT, Mason MD, Mead GM et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 2005; 366: 293-300.
65. Oliver TD, Steiner K, Skoneczna H et al. Pooled analysis of phase II reports of 2 vs. 1 course of carboplatin as adjuvant for stage 1 seminoma. J Clin Oncol 2005; 23 (Suppl): 395s (abstr 4572).
66. Reiter WJ, Brodowicz T, Alavi S et al. Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma. J Clin Oncol 2001; 19: 101-104.
67. Krege S, Beyer J, Souchon R, European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol 2008; 53: 478-496. (Review).
68. Sogani PC, Perrotti M, Herr HW et al. Clinical stage I testis cancer: Long-term outcome of patients on surveillance. J Urol 1998; 159: 855-858. (Pubitemid 28106543)
69. Heidenreich A, Sesterhenn IA, Mostofi FK, Moul JW. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer 1998; 83: 1002-1011.
70. Jones RH, Vasey PA. Part I: testicular cancer-management of early disease. Lancet Oncol 2003; 4: 730-737 (Review).
71. Oliver RT, Ong J, Shamash J et al. Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with stage 1 nonseminoma treated with adjuvant chemotherapy. Urology 2004; 63: 556-561.
72. Albers P, Siener R, Krege S et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 2008; 26: 2966-2972.
73. Tandstad T, Dahl O, Cohn-Cedermark G et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol 2009; 27: 2122-2128.
74. Warde P, Gospodarowicz M, Panzarella T et al. Management of stage II seminoma. J Clin Oncol 1998; 16: 290-294.
75. Krege S, Boergermann C, Baschek R et al. Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG). Ann Oncol 2006; 17: 276-280.
76. Weissbach L, Bussar-Maatz R, Lohrs U et al. Prognostic factors in seminomas with special respect to HCG: results of a prospective multicenter study. Seminoma Study Group. Eur Urol 1999; 36: 601-608.
77. Mencel PJ, Motzer RJ, Mazumdar M et al. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol 1994; 12: 120-126. (Pubitemid 2029119)
78. Albers P, Albrecht W, Algaba F et al. Guidelines on testicular cancer. Eur Urol 2005; 48: 885-894.
79. Jones RH, Vasey PA. Part II: testicular cancer-management of advanced disease. Lancet Oncol 2003; 4: 738-747.
80. Krege S, Beyer J, Souchon R et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol 2008; 53: 497-513.
81. Feldman DR, Bosl GJ, Sheinfeld J et al. Medical treatment of advanced testicular cancer. JAMA 2008; 299: 672-684.
82. Mannuel HD, Hussain A. Update on testicular germ cell tumors. Curr Opin Oncol 2009; 21: 254-259.
83. Motzer RJ, Agarwal N, Beard C et al. NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw 2009; 7: 672-693.
84. Saxman SB, Finch D, Gonin R, Einhorn LH. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indiana University experience. J Clin Oncol 1998; 16: 702-706.
85. de Wit R, Roberts JT, Wilkinson PM et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001; 19: 1629-1640.
86. Toner GC, Stockier MR, Boyer MJ et al. Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group. Lancet 2001; 357: 739-745.
87. Culine S, Kerbrat P, Kramar A et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol 2007; 18: 917-952. (Pubitemid 47054091)
88. Horwich A, Sleijfer DT, Fossa SD et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic non-seminomatous germ cell cancer a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997; 15: 1844-1852. (Pubitemid 27209513)
89. Fossa SD, de Wit R, Roberts JT et al. Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20). J Clin Oncol 2003; 21: 1107-1118.
90. Hinton S, Catalano PJ, Einhorn LH et al. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors. Cancer 2003; 97: 1869-1875.
91. Broun ER, Nichols CR, Gize G et al. Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer. Cancer 1997; 79: 1605-1610.
92. Motzer RJ, Nichols CJ, Margolin KA et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 2007; 25: 247-256.
93. Flechon A, Bompas E, Biron P, Droz JP. Management of post-chemotherapy residual masses in advanced seminoma. J Urol 2002; 168: 1975-1979.
94. De Santis M, Bokemeyer C, Becherer A et al. Predictive impact of 2-(18) fluoro-2-deoxy-d-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 2001; 19: 3740-3744.
95. Ravi R, Ong J, Oliver RT et al. The management of residual masses after chemotherapy in metastatic seminoma. BJU Int 1999; 83: 649-653.
96. De Santis M, Becherer A, Bokemeyer C et al. 2-18 fluoro-deoxy-D-glucose Positron Emission Tomography Is a Reliable Predictor for Viable Tumor in Postchemotherapy Seminoma: An Update of the Prospective Multicentric SEMPET Trial. J Clin Oncol 2004; 22: 1034-1039. (Pubitemid 41095035)
97. Spiess PE, Brown GA, Liu P et al. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer 2006; 107: 1483-1490. (Pubitemid 44546907)
98. Eggener SE, Carver BS, Loeb S et al. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. Cancer 2007; 109: 528-535.
99. Carver BS, Shayegan B, Serio A et al. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. J Clin Oncol 2007; 25: 1033-1037.
100. Oechsle K, Hartmann M, Brenner W et al. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: The German Multicenter Positron Emission Tomography Study Group. J Clin Oncol 2008; 26: 5930-5935.
101. Fizazi K, Tjulandin S, Salvioni R et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy-results from an international study group. J Clin Oncol 2001; 19: 2647-2657. (Pubitemid 32441369)
102. Steyerberg EW, Donohue JP, Gerl A et al. Residual masses after chemotherapy for metastatic testicular cancer: The clinical implications of the association between retroperitoneal and pulmonary histology. Re-analysis of Histology in Testicular Cancer (ReHiT) Study Group. J Urol 1997; 158: 474-478.
103. Hartmann JT, Candelaria M, Kuczyk MA et al. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer 1997; 33: 84-87.
104. See WA, Laurenzo JF, Dreicer R, Hoffman HT. Incidence and management of testicular carcinoma metastatic to the neck. J Urol 1996; 155: 590-592.
105. Rivoire M, Elias D, De Cian F et al. Multimodality treatment of patients with liver metastases from germ cell tumors: The role of surgery. Cancer 2001; 92: 578-587. (Pubitemid 32735193)
106. Fossa SD, Bokemeyer C, Gerl A, Culine S. Treatment outcome of patients with brain metastases from malignant germ cell tumors. Cancer 1999; 85: 988-997.
107. Einhorn LH, Williams SD, Chamness A et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007; 357: 340-348.
108. Mead GM, Cullen MH, Huddart R et al. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer 2005; 93: 178-184.
109. Albers P, Ganz A, Hannig E et al. Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol 2000; 164: 381-384. (Pubitemid 30481930)
110. Vuky J, Tickoo SK, Sheinfeld J et al. Salvage chemotherapy for patients with advanced pure seminoma. J Clin Oncol 2002; 20: 297-301.
111. Beyer J, Kramar A, Mandanas R et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 1996; 14: 2638-2645.
112. Loehrer PJ Jr, Gonin R, Nichols CR et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 1998; 16: 2500-2504. (Pubitemid 28309047)
113. Kondagunta GV, Bacik J, Sheinfeld J et al. Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol 2007; 25: 85-90.
114. Beyer J, Stenning S, Gerl A et al. High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. Ann Oncol 2002; 13: 599-605.
115. Einhorn LH, Brames MJ, Juliar B, Williams SD. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. J Clin Oncol 2007; 25: 513-516. (Pubitemid 350002957)
116. Bedano PM, Brames MJ, Williams SD et al. Phase II study of cisplatin plus epirubicin salvage chemotherapy in refractory germ cell tumors. J Clin Oncol 2006; 24: 5403-5407. (Pubitemid 46623172)
117. Kollmannsberger C, Beyer J, Liersch R et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2004; 22: 108-114.
118. Bokemeyer C, Oechsle K, Honecker F et al. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol 2008; 19: 448-453.
119. Sharp DS, Carver BS, Eggener SE et al. Clinical outcome and predictors of survival in late relapse of germ cell tumors. J Clin Oncol 2008; 26: 5524-5534.
120. Oldenburg J, Martin JM, Fossa SD. Late relapses of germ cell malignancies: incidence, management, and prognosis. J Clin Oncol 2006; 24: 5503-5511. (Pubitemid 46631330)
121. Aparicio J, Garcia del Muro X, Maroto P et al. Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol 2003; 14: 867-872. (Pubitemid 36827202)
122. Choo R, Thomas G, Woo T et al. Long-term outcome of postorchiectomy surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys 2005; 61: 736-740.
123. Evans CP. Follow-up strategies for genitourinary malignancies. Cancer 2002; 94: 2892-2895.
124. Kondagunta GV, Sheinfeld J, Motzer RJ. Recommendations of follow-up after treatment of germ cell tumors. Semin Oncol 2003; 30: 382-389.
125. Oh W, Richie J. Posttreatment follow-up for men with testicular germ cell tumors. Retrieved Nov 15 2009 from UpToDate edition 17.3 online textbook: http://www.uptodate.com
126. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. http://www.nccn.org/professionals/physician-gls/f- guidelines.asp (accessed on 19/11/2009).
127. Spiess PE, Brown GA, Liu P et al. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection. J Urol 2007; 177: 131-138.
128. Comis RL. Detecting bleomycin pulmonary toxicity: a continued conundrum. J Clin Oncol 1990; 8: 765-767.
129. Petersen PM, Hansen SW. The course of long-term toxicity in patients treated with cisplatin-based chemotherapy for non-seminomatous germ-cell cancer. Ann Oncol 1999; 10: 1475-1483.
130. Osanto S, Bukman A, Van Hoek F et al. Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol 1992; 10: 574-579.
131. Huyghe E, Matsuda T, Daudin M et al. Fertility after testicular cancer treatments: results of a large multicenter study. Cancer 2004; 100: 732-737.
132. van den Belt-Dusebout AW, Nuver J, de Wit R et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006; 24: 467-475. (Pubitemid 46630466)
133. van den Belt-Dusebout AW, de Wit R, Gietema JA et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007; 25: 4370-4378.
134. Nuver J, Smit AJ, Wolffenbuttel BH et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 2005; 23: 3718-3725.
135. Fossa SD, Aass N, Harvei S, Tretli S. Increased mortality rates in young and middle-aged patients with malignant germ cell tumours. Br J Cancer 2004; 90: 607-612. (Pubitemid 38297198)
136. Travis LB, Fossa SD, Schonfeld SJ et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005; 97: 1354-1365.
137. Houck W, Abonour R, Vance G, Einhorn LH. Secondary leukemias in refractory germ cell tumor patients undergoing autologous stem-cell transplantation using high-dose etoposide. J Clin Oncol 2004; 22: 2155-2158. (Pubitemid 41095149)